5α-reductase inhibitors impact prognosis of urothelial carcinoma | BMC Cancer | Full Text

5α-reductase inhibitors impact prognosis of urothelial carcinoma | BMC Cancer | Full Text

5α-reductase inhibitors impact prognosis of urothelial carcinoma

5α-reductase inhibitors (5-ARIs) inhibit the pathway of converting the testosterone to dihydrotestosterone and are widely used in benign prostatic hyperplasia patients. Since androgen receptor activation may p...

Authors:Chien-Sheng Wang, Ching-Chia Li, Yung-Shun Juan, Wen-Jeng Wu and Hsiang-Ying Lee

Citation:BMC Cancer 2020 20:872

Content type:Research article

 

Published on: 11 September 2020

• ViewFull Text
 
• ViewPDF